Relative Value Partners Group’s Bristol-Myers Squibb BMY Stock Holding History

Relative Value Partners Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$567K	Buy	+13,658	New	+$611K	0.07%	204

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Relative Value Partners Group's BMY Position: Q2 2024 in Review

Relative Value Partners Group opened a new position in Bristol-Myers Squibb (BMY) in Q2 2024: 13,658 shares worth $567K. The stake represents 0.07% of the portfolio and ranks #204 among its holdings.

2,152 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

Relative Value Partners Group held 13,658 shares of Bristol-Myers Squibb worth $567K as of Q2 2024.
Bristol-Myers Squibb was a new Relative Value Partners Group position in Q2 2024.
Bristol-Myers Squibb made up 0.07% of Relative Value Partners Group's portfolio in Q2 2024, its #204 holding.
2,152 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Relative Value Partners Group's 13F filing for Q2 2024, filed 12 Jul 2024.